A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

Exclusion Criteria

• •1. Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccines;
• •2. Previous vaccination against influenza in 2008 or 2009 with seasonal trivalent inactivated influenza vaccine;
• •3. Known history of Guillain-Barré Syndrome;
• •4. Clinical signs of active infection and/or an oral temperature of greater than or equal to 100 degrees F (37.8 degrees C).
• •5. Have active or recent and clinically significant gastrointestinal/hepatic, renal, neurological, cardiovascular, respiratory, endocrine disorders or other medical disorders;
• •6. History of seizures;
• •7. Confirmed or suspected immunosuppressive condition, or a previously diagnosed immunodeficiency disorder;
• •8. Clinically significant history of malignancy
• •9. Current treatment, or treatment with radiotherapy or cytotoxic drugs at any time during the six months prior to administration of the Study Vaccine;
• •10. Current immunosuppressive or immunomodulative therapy;
• •11. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the Study Vaccine;
• •12. Participation in a clinical trial or use of an investigational compound within 30 days prior to receiving the Study Vaccine ;
• •13. Vaccination with a registered vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to receiving the Study Vaccine.
• •14. Current treatment with warfarin or other anticoagulants;
• •15. Major congenital defects;
• •16. Evidence, or history (within the previous 12 months) of drug or alcohol abuse;
• •17. Unwillingness or inability to comply with the study protocol including completion of adverse event diary cards;
• •18. History of psychiatric disorders;
• •19. Resident of long term care facility.